secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0000950170-25-048033
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports early REVEAL-1 data suggests Revita prevents weight regain after GLP-1 stop
--------------------------------------------------------------------------------

- First 7 patients showed average weight regain of 1.2% at 1 month vs typical ~3% after GLP-1 discontinuation.
- No safety or tolerability concerns in 15 patients treated to date; consistent with prior pooled data.
- REMAIN-1 pivotal study now >50% enrolled; full enrollment expected summer 2025; midpoint analysis Q3 2025.
- Revita holds FDA Breakthrough Device designation for post-GLP-1 weight maintenance.
- Additional REVEAL-1 follow-up data expected in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025048033/0000950170-25-048033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025048033/guts-20250401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-048033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer